Opinion|Videos|April 24, 2024

Impressions on Safety Data from EMERALD Subgroup Analysis

Expert perspectives on safety data from the EMERALD subgroup analysis, highlighting endocrine therapy–related adverse effects and supportive care strategies.


Latest CME